In line with the previous study, we found CLAG and FLAG achieved median OS of 12.0 (95% CI 8.4–15.6) months and 8.0 (95% CI 5.1–10.9) months, respectively, while no difference of OS was observed, and this satisfactory OS might be on account of the fact that: (1) the synergistic effect of purine analogs and Ara-C leads to a strong anti-leukemia effect through cytotoxic effects [22]; (2) for long-term survival, G-CSF improves the hematopoietic activity by promoting the differentiation of myeloid cells [18]. The gene discussed is CSF3; the disease is leukemia.